These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 28396911)

  • 1. Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician.
    Lheureux S; Denoyelle C; Ohashi PS; De Bono JS; Mottaghy FM
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):41-54. PubMed ID: 28396911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside.
    Yamazaki S; Spilker ME; Vicini P
    Expert Opin Drug Metab Toxicol; 2016; 12(3):253-65. PubMed ID: 26799750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy.
    Wahl RL; Chareonthaitawee P; Clarke B; Drzezga A; Lindenberg L; Rahmim A; Thackeray J; Ulaner GA; Weber W; Zukotynski K; Sunderland J
    J Nucl Med; 2021 Jan; 62(1):6-14. PubMed ID: 33334911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonotyping for precision oncology.
    Dang HX; Maher CA
    Drug Discov Today; 2015 Dec; 20(12):1464-9. PubMed ID: 26494143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecularly targeted cancer therapy: some lessons from the past decade.
    Huang M; Shen A; Ding J; Geng M
    Trends Pharmacol Sci; 2014 Jan; 35(1):41-50. PubMed ID: 24361003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.
    Barbieri CE; Chinnaiyan AM; Lerner SP; Swanton C; Rubin MA
    Eur Urol; 2017 Feb; 71(2):237-246. PubMed ID: 27567210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
    Ludwig WD
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker Tests for Molecularly Targeted Therapies: Laying the Foundation and Fulfilling the Dream.
    Lyman GH; Moses HL
    J Clin Oncol; 2016 Jun; 34(17):2061-6. PubMed ID: 27069080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of the NCI precision medicine trials-NCI MATCH and MPACT.
    Do K; O'Sullivan Coyne G; Chen AP
    Chin Clin Oncol; 2015 Sep; 4(3):31. PubMed ID: 26408298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy in cancer.
    Tsimberidou AM
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1113-32. PubMed ID: 26391154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The journey toward personalized cancer therapy.
    Tulbah A; Chaudhri N; Al Dayel F; Akhtar M
    Adv Anat Pathol; 2014 Jan; 21(1):36-43. PubMed ID: 24316909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear medicine theranostics comes of age.
    Herrmann K; Kraus BJ; Hadaschik B; Kunikowska J; van Poppel H; N'Dow J; Sartor O; Oyen WJG
    Lancet Oncol; 2021 Nov; 22(11):1497-1498. PubMed ID: 34735807
    [No Abstract]   [Full Text] [Related]  

  • 15. Implementing precision medicine initiatives in the clinic: a new paradigm in drug development.
    Hollebecque A; Massard C; Soria JC
    Curr Opin Oncol; 2014 May; 26(3):340-6. PubMed ID: 24709975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A promising cancer diagnosis and treatment strategy: targeted cancer therapy and imaging based on antibody fragment.
    Zhao X; Ning Q; Mo Z; Tang S
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3621-3630. PubMed ID: 31468992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.
    Venkatakrishnan K; Friberg LE; Ouellet D; Mettetal JT; Stein A; Trocóniz IF; Bruno R; Mehrotra N; Gobburu J; Mould DR
    Clin Pharmacol Ther; 2015 Jan; 97(1):37-54. PubMed ID: 25670382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapies of solid cancers: new options, new challenges.
    Awada A; Aftimos PG
    Curr Opin Oncol; 2013 May; 25(3):296-304. PubMed ID: 23493191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Nuclear medicine diagnostics, therapy and theranostics in the context of modern oncology].
    Schaefer N; Prior J
    Ther Umsch; 2019 Sep; 76(4):167-172. PubMed ID: 31498036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative Imaging in Cancer Clinical Trials.
    Yankeelov TE; Mankoff DA; Schwartz LH; Lieberman FS; Buatti JM; Mountz JM; Erickson BJ; Fennessy FM; Huang W; Kalpathy-Cramer J; Wahl RL; Linden HM; Kinahan PE; Zhao B; Hylton NM; Gillies RJ; Clarke L; Nordstrom R; Rubin DL
    Clin Cancer Res; 2016 Jan; 22(2):284-90. PubMed ID: 26773162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.